Bio-Rad Laboratories, Inc. has been under the spotlight due to its recent third-quarter results, with analysts revising their estimates. The company has seen a 52-week high in its stock price, thanks to robust growth, and an upgrade from analysts. DekaBank Deutsche Girozentrale possesses over $4 million worth of Bio-Rad's stocks. Q3 earnings surpassed estimates, contributing to a significant rise in net income. Despite this, the company could potentially face a slowdown. The company's price target was raised to $450 from $400 by Citi, but the stock value dropped by 4.6% over the past week, marking a 58% loss for shareholders. Future outlook seems tentative amidst speculation about continued holding of Bio-Rad stock in portfolios. The growth prospects look overvalued according to some analysts, while others suggest they may have escalated too quickly. The firm cut its annual revenue forecast due to weak demand for diagnostics products, and the COO sold $990k in company shares. However, Bio-Rad has reiterated its revenue growth outlook for 2024 despite some setbacks.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sat, 02 Nov 2024 12:23:27 GMT -
Rating 4
- Innovation -6
- Information 6
- Rumor -7
